Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Three-Dimensional Rotational Angiography Guidance for Atrial Leadless Pacemaker Implantation.

Heart rhythm·2026

Same author

Synovial histopathology in rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs: an analysis of 1593 surgical specimens using the Rooney score.

EULAR rheumatology open·2026

Same author

Wild-type transthyretin amyloid cardiomyopathy diagnosed by <sup>99m</sup>Tc-HMDP scintigraphy and an endomyocardial biopsy despite inconclusive <sup>99m</sup>Tc-PYP findings.

Journal of cardiology cases·2026

Same author

A Step-Up Underwater Endoscopic Mucosal Resection Strategy with Rescue Underwater Injection Endoscopic Mucosal Resection for Non-Pedunculated Colorectal Lesions.

DEN open·2026

Same author

Takotsubo syndrome following delayed bleeding after gastric endoscopic submucosal dissection: a case report.

Clinical journal of gastroenterology·2026

Same author

The Design of Metal Ion-Induced Dimers Suggestive of 3D Domain Swapping.

Chembiochem : a European journal of chemical biology·2026

Search research articles

Related Experiment Video

Updated: Mar 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

[DMARDs (Focusing on iguratimod)].

Satoshi Ito

Nihon Rinsho. Japanese Journal of Clinical Medicine

|June 18, 2016

Summary

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) effective for rheumatoid arthritis. It offers flexible use, including monotherapy or combination therapy, and may support biologics-free treatment strategies.

Area of Science:

Rheumatology
Immunology
Pharmacology

Background:

Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) are mainstays in rheumatoid arthritis (RA) treatment.
Methotrexate (MTX) is an anchor csDMARD, but alternatives are needed for diverse patient populations and treatment strategies.
Iguratimod (IGU) is a newly developed csDMARD with a distinct mechanism of action.

Purpose of the Study:

To evaluate the potential applications and efficacy of iguratimod (IGU) in rheumatoid arthritis (RA) management.
To explore IGU's utility as monotherapy, in combination with other csDMARDs, and in relation to MTX and biologic therapies.
To assess IGU's role in achieving and maintaining a biologics-free state in RA patients.

Main Methods:

This study reviews the pharmacological profile and clinical applications of iguratimod (IGU).

More Related Videos

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Related Experiment Videos

Last Updated: Mar 19, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

It analyzes IGU's efficacy in monotherapy and combination regimens with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).

The potential of IGU in MTX-based and biologic-based treatment strategies, including biologics-free conditions, is discussed.

Main Results:

Iguratimod (IGU) demonstrates efficacy in monotherapy and combination therapy with other csDMARDs.
IGU is suitable for patients with complications due to its non-immunosuppressive immunological reaction profile.
IGU can be used as an initial csDMARD before MTX initiation or for reinforcing MTX and biologic therapies.

Conclusions:

Iguratimod (IGU) offers a versatile treatment option for rheumatoid arthritis (RA) across various clinical scenarios.
Its unique mechanism allows for flexible use, including in patients with comorbidities and as part of strategies to reduce or eliminate biologic use.
IGU has the potential to become a globally adopted standard csDMARD originating from Japan.